Issue 38, 2025

Sodium alginate/polyvinylpyrrolidone/lapatinib-loaded Zr–metal organic framework: biocompatibility evaluation and pH-responsive in vitro drug release for oral delivery applications

Abstract

Recent advancements in drug delivery systems have transformed drug administration methods to ensure precise, targeted delivery with minimal side effects. Innovations involving polymer–metal organic frameworks can significantly improve drug stability and controlled release properties. In this study, a drug delivery system based on a zirconium metal organic framework (Zr-MOF), sodium alginate (SA), and polyvinylpyrrolidone (PVP) was developed. Lapatinib, an oral anticancer drug used to treat breast cancer, was incorporated into the pores of a Zr–metal organic framework. Although lapatinib selectively inhibits HER2 receptors and cancer cell proliferation, it has limitations, primarily due to its poor oral bioavailability and side effects resulting from its toxicity. To address these issues, we embedded a drug-loaded Zr–metal organic framework in a sodium alginate (SA)/polyvinylpyrrolidone (PVP) polymer matrix. This combination has been proposed to modulate drug release characteristics, promote pH-responsive targeted drug delivery, increase stability, enhance mechanical properties (tensile strength of 6.5 MPa), improve hydrophilicity, and potentially enhance biocompatibility of the composites. In vitro release studies showed minimal lapatinib release (13%) over 48 h under simulated gastric conditions (pH 1.2), whereas drug release reached 91% at intestinal pH (6.8) during the same period. These findings indicate that the system can intrinsically prevent premature gastric release, emphasizing its potential to achieve high therapeutic effects at lower doses with reduced side effects. Biocompatibility assays indicated over 94% viability in the relevant cell lines after 24 and 48 h, indicating the favorable cytocompatibility of the composites. Overall, this composite platform provides controlled, sustained, and site-specific release of lapatinib, which could potentially enhance oral bioavailability, reduce dosage frequency, and systemic toxicity.

Graphical abstract: Sodium alginate/polyvinylpyrrolidone/lapatinib-loaded Zr–metal organic framework: biocompatibility evaluation and pH-responsive in vitro drug release for oral delivery applications

Article information

Article type
Paper
Submitted
17 Jun 2025
Accepted
21 Aug 2025
First published
04 Sep 2025
This article is Open Access
Creative Commons BY-NC license

J. Mater. Chem. B, 2025,13, 12205-12223

Sodium alginate/polyvinylpyrrolidone/lapatinib-loaded Zr–metal organic framework: biocompatibility evaluation and pH-responsive in vitro drug release for oral delivery applications

S. Rajeev, N. Hasoon K T and U. G. Panicker, J. Mater. Chem. B, 2025, 13, 12205 DOI: 10.1039/D5TB01449B

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements